newsfilter
← Latest News
Business Wire·

Dicerna to Participate in 16th Annual Citi Biopharma Conference

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer,